



PTO/SB/08a/b (08-03)


Approved for use through 07/31/2005. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/766106
				Filing Date	January 27, 2004
				First Named Inventor	Lewis, Danny
				Art Unit	1615
				Examiner Name	Azpuru, Carlos A.
Sheet	1	of	2	Attorney Docket Number	PRJ-006CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	5,102,872	04/92	Singh <i>et al.</i>	
	A2	5,672,662	09/97	Harris <i>et al.</i>	
	A3	4,179,337	12/79	Davis <i>et al.</i>	
	A4	5,320,840	06/94	Camble <i>et al.</i>	
	A5	5,446,090	08/95	Harris	
	A6	5,880,255	03/99	Delgado <i>et al.</i>	
	A7	5,942,253	08/99	Gombotz <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	A8	WO 98/46212 A1	10/98	Amgen Inc.		
	A9	WO 02/41829 A2, A3	05/02	Dunn James M. <i>et al.</i>		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A10	Bently, <i>et al.</i> "PEG Biphalin: A Potent Long-Acting Analgesic" <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</i> , 28:1287-1288 (2001);	
	A11	Diwan <i>et al.</i> "Pegylation enhances protein stability during encapsulation in PLGA microspheres." <i>J. Controlled Release</i> , 73:233-244(2001);	
	A12	Diwan <i>et al.</i> "Stabilization of Recombinant Interferon-alpha by Pegylation for Encapsulation in PLGA Microspheres." <i>Int. J. Pharm.</i> 252 :111-122 (2003);	
	A13	Hora, <i>et al.</i> "Controlled Release of Interleukin-2 from Biodegradable Microspheres" <i>BIO/TECHNOLOGY</i> 8: 755-758 (August 1990).	
	A14	Hora, <i>et al.</i> "Development of a Controlled Release Microsphere Formulation of Interleukin-2" <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> 16:509-510 (1989);	
	A15	Katre, <i>et al.</i> "Chemimcal Modification of Recombinant Interleukin 2 by Polyethylene Glycol Increases its Potency in the Murine Meth A Sarcoma Model" <i>Proc. Natl. Acad. Sci. USA</i> 84:1487-1491 (1987);	
	A16	Katre, <i>et al.</i> "Immunogenicity of Recombinant IL-2 Modified by Covalent Attachment of Polyethylene Glycol" <i>J. Immunol.</i> 144:209-213 (1990);	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

3/4/05



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/766106
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	January 27, 2004
				First Named Inventor	Lewis, Danny
				Art Unit	1615
				Examiner Name	Azpuru, Carlos A.
Sheet	2	of	2	Attorney Docket Number	PRJ-006CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	Kim et al. "Controlled release of PEGylated peptides from poly(lactic-co-glycolic acid) microspheres." <i>Proceed. Int'l Symp. Control. Rel. Bioact. Mater.</i> 28 : #6175 (2001);	
	B2	Kim et al. "Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres." <i>Biomaterials</i> 23:2311-2317 (2002);	
	B3	Lam et al. "Sustained release of PEGylated monoclonal antibody fragments from drug delivery systems." <i>Proceed. Int'l Symp. Control. Rel. Bioact. Mater.</i> 29 : #037 (2002);	
	B4	Lam et al. "Integrity of PEGylated monoclonal antibody fragment in polymeric matrices." <i>Proceed. Int'l Symp. Control. Rel. Bioact. Mater.</i> 30 : #449 (2003);	
	B5	Misicka, et al. "Structure-Activity Relationship of Biphalin. The Synthesis and Biological Activities of New Analogues with Modifications in Positions 3 and 4." <i>Life Sciences</i> 60(15):1263-1269 (1997);	
	B6	Yip, et al. "Direct Force Measurements of Insulin Monomer—Monomer Interactions" <i>Biochemistry</i> 37(16):5439-5449 (1998).	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

3/5/05